N@N

EBS SqueezeTrigger Price is $25.58. There is $112,699,721 That Short Sellers Still Need To Cover.

November 7, 2016 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net is monitoring Emergent BioSolutions Inc. (NYSE:EBS) in real time and just received an alert that EBS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 4369900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $25.58. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net .

From August 2009 to October 2016, an aggregate amount of 218069673 shares of EBS have been shorted for a total dollar value of $5451741825. The EBS SqueezeTrigger price of $25.58 is the volume weighted average price that all shorts are short in shares of EBS. There is still approximately $112,699,721 of potential short covering in shares of EBS.

Buyins.net has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.buyins.net .

Emergent BioSolutions Inc. (NYSE:EBS) - Emergent BioSolutions, Inc., a specialty biopharmaceutical company, develops, manufactures, and sells specialized products to healthcare providers and governments in the United States and internationally. The company s Biodefense division markets BioThrax to treat anthrax disease; Anthrasil for the treatment of inhalational anthrax; BAT to treat botulinum disease; VIGIV to address the adverse events from smallpox vaccination; and RSDL for the removal or neutralization of chemical agents, T-2 toxins, and various pesticide-related chemicals from the skin. This division is also developing NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072, the compound in the EV-035 series of broad spectrum antibiotics for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine; and PreviThrax, a recombinant protective antigen anthrax vaccine, as well as other products addressing public health threats and emerging infectious diseases. Its Aptevo division markets IXINITY to prevent bleeding episodes in people with hemophilia B; WinRho SDF to treat autoimmune platelet disorders and hemolytic disease of the newborn; HepaGam B for the post-exposure prophylactic treatment of hepatitis-B; and VARIZIG for the post-exposure prophylactic treatment of varicella zoster virus. This division s investigational stage product candidates include otlertuzumab, a protein therapeutic for Chronic Lymphocytic Leukemia; MOR209/ES414 for metastatic castration resistant prostate cancer under collaboration with MorphoSys AG; ES210, a protein therapeutic for inflammation-related indications; 5E3, a monoclonal antibody therapeutic for Alzheimer's disease; and other protein therapeutic product candidates primarily for the treatment of immuno-oncology. In addition, the company provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland..

The SqueezeTrigger database of billions of short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---